NICE Publishes Draft Recommendation for Boehringer’s Pradaxa
England and Wales’ cost regulator, NICE, have released draft regulatory guidance recommending the expanded use of Boehringer Ingelheim’s clot buster drug Pradaxa on the National Health Service (NHS).
The National Institute for Health and Care Excellence (NICE) has endorsed the drug to treat and prevent recurrent and potentially fatal blood clots in the legs and lungs.
The National Institute for Health and Care Excellence has previously granted regulatory approval for Pradaxa to prevent venous thrombembolic events in adults who have undergone elective total hip or total knee replacement surgery, and for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).
Patients with suspected deep vein thrombosis or pulmonary embolism are usually treated immediately with bloodthinners, most commonly with injections of low molecular weight heparin, and once the diagnosis has been confirmed this is then overlapped with an oral anticoagulant such as warfarin.
But using warfarin can present difficulties, as the drug is associated with a high bleeding risk, so patients must to be monitored on a frequent basis to ensure that the blood is clotting properly.
NICE noted that while the most plausible incremental cost effectiveness ratio for Pradaxa compared with warfarin for acute treatment was uncertain, both the company’s and the Expert Review Group’s estimates fell within the value for money range.